Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia
Protocol ID
CFZ2008 / 20140106
Disease (Sub Disease)
Acute Lymphoblastic Leukaemia (ALL)
Diagnosis Stage
Relapse/refractory
Location
NSW, QLD, VIC, WA
Sponsor
Amgen
Collaborators
Therapeutic Advances in Childhood Leukemia & Lymphoma
Innovative Therapies For Children with Cancer Consortium
Innovative Therapies For Children with Cancer Consortium
Links
Trial Status
Open
Sites
Queensland Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
Perth Children's Hospital
The Children's Hospital at Westmead
Sydney Children's Hospital
Royal Children's Hospital
Perth Children's Hospital
The Children's Hospital at Westmead
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
1 Month to 21 Years
International registry ID's
NCT02303821
| Study Title | Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia |
|---|---|
| Protocol ID | CFZ2008 / 20140106 |
| Disease (Sub Disease) | Acute Lymphoblastic Leukaemia (ALL) |
| Diagnosis Stage | Relapse/refractory |
| Location | NSW / QLD / VIC / WA |
| Sponsor | Amgen |
| Collaborators | Therapeutic Advances in Childhood Leukemia & Lymphoma/ Innovative Therapies For Children with Cancer Consortium/ |
| Links | https://clinicaltrials.gov/ct2/show/NCT02303821 |
| Trial Status | Open |
| Trial Open Date | 10/09/2015 |
| Sites | Queensland Children's Hospital / Sydney Children's Hospital / Royal Children's Hospital/ Perth Children's Hospital/ The Children's Hospital at Westmead |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 1 Month to 21 Years |
| International registry ID's | NCT02303821 |